<VariationArchive VariationID="15417" VariationName="NM_000518.5(HBB):c.126_129del (p.Phe42fs)" VariationType="Deletion" Accession="VCV000015417" Version="124" RecordType="classified" NumberOfSubmissions="22" NumberOfSubmitters="22" DateLastUpdated="2024-07-29" DateCreated="2017-03-22" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="30456" VariationID="15417">
      <GeneList>
        <Gene Symbol="HBB" FullName="hemoglobin subunit beta" GeneID="3043" HGNC_ID="HGNC:4827" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>11p15.4</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="5225464" stop="5227071" display_start="5225464" display_stop="5227071" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="5246695" stop="5248300" display_start="5246695" display_stop="5248300" Strand="-" />
          </Location>
          <OMIM>141900</OMIM>
        </Gene>
        <Gene Symbol="LOC106099062" FullName="HBB recombination region" GeneID="106099062" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>11p15.4</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="5226570" stop="5228834" display_start="5226570" display_stop="5228834" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="LOC107133510" FullName="origin of replication at HBB" GeneID="107133510" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>11p15.4</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="5222166" stop="5229620" display_start="5222166" display_stop="5229620" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000518.5(HBB):c.126_129del (p.Phe42fs)</Name>
      <CanonicalSPDI>NC_000011.10:5226762:AAAGAA:AA</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>11p15.4</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="5226763" stop="5226766" display_start="5226763" display_stop="5226766" variantLength="4" positionVCF="5226762" referenceAlleleVCF="CAAAG" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="5247993" stop="5247996" display_start="5247993" display_stop="5247996" variantLength="4" positionVCF="5247992" referenceAlleleVCF="CAAAG" alternateAlleleVCF="C" />
      </Location>
      <OtherNameList>
        <Name>41/42-TTCT</Name>
        <Name>CD 41/42 (-CTTT)</Name>
      </OtherNameList>
      <ProteinChange>F42fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.10" sequenceAccession="NC_000011" sequenceVersion="10" change="g.5226765_5226768del" Assembly="GRCh38">
            <Expression>NC_000011.10:g.5226765_5226768del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.9" sequenceAccession="NC_000011" sequenceVersion="9" change="g.5247995_5247998del" Assembly="GRCh37">
            <Expression>NC_000011.9:g.5247995_5247998del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_000007.3" sequenceAccession="NG_000007" sequenceVersion="3" change="g.70850_70853del">
            <Expression>NG_000007.3:g.70850_70853del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_042296.1" sequenceAccession="NG_042296" sequenceVersion="1" change="g.296_299del">
            <Expression>NG_042296.1:g.296_299del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_046672.1" sequenceAccession="NG_046672" sequenceVersion="1" change="g.4700_4703del">
            <Expression>NG_046672.1:g.4700_4703del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_059281.1" sequenceAccession="NG_059281" sequenceVersion="1" change="g.5306_5309del">
            <Expression>NG_059281.1:g.5306_5309del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000518.5" sequenceAccession="NM_000518" sequenceVersion="5" change="c.126_129del" MANESelect="true">
            <Expression>NM_000518.5:c.126_129del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000509.1" sequenceAccession="NP_000509" sequenceVersion="1" change="p.Phe42fs">
            <Expression>NP_000509.1:p.Phe42fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1232" sequenceAccession="LRG_1232">
            <Expression>LRG_1232:g.5306_5309del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1232t1" sequenceAccession="LRG_1232t1">
            <Expression>LRG_1232t1:c.126_129del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1232p1" sequenceAccession="LRG_1232p1" change="p.Phe42fs">
            <Expression>LRG_1232p1:p.Phe42fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000518.5" sequenceAccession="NM_000518" sequenceVersion="5" change="c.126_129delCTTT" MANESelect="true">
            <Expression>NM_000518.5:c.126_129delCTTT</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000518.4" sequenceAccession="NM_000518" sequenceVersion="4" change="c.124_127delTTCT">
            <Expression>NM_000518.4:c.124_127delTTCT</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="849" DB="HBVAR" />
        <XRef ID="CA125284" DB="ClinGen" />
        <XRef ID="GTR000500319" DB="Genetic Testing Registry (GTR)" />
        <XRef ID="GTR000556525" DB="Genetic Testing Registry (GTR)" />
        <XRef ID="GTR000562167" DB="Genetic Testing Registry (GTR)" />
        <XRef Type="Allelic variant" ID="141900.0326" DB="OMIM" />
        <XRef Type="rs" ID="80356821" DB="dbSNP" />
      </XRefList>
      <GlobalMinorAlleleFrequency Value="0.00100" Source="1000 Genomes Project" MinorAllele="AA" />
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000518.5(HBB):c.126_129del (p.Phe42fs) AND Beta zero thalassemia" Accession="RCV000016673" Version="37">
        <ClassifiedConditionList TraitSetID="4683">
          <ClassifiedCondition DB="MedGen" ID="C0271980">Beta zero thalassemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2002-09-28" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.126_129del (p.Phe42fs) AND beta Thalassemia" Accession="RCV000020328" Version="25">
        <ClassifiedConditionList TraitSetID="4697">
          <ClassifiedCondition DB="MedGen" ID="C0005283">beta Thalassemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2019-12-09" SubmissionCount="6">Pathogenic/Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.126_129del (p.Phe42fs) AND not provided" Accession="RCV000508554" Version="32">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-01-31" SubmissionCount="7">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.126_129del (p.Phe42fs) AND Hb SS disease" Accession="RCV001004569" Version="9">
        <ClassifiedConditionList TraitSetID="4606">
          <ClassifiedCondition DB="MedGen" ID="C0002895">Hb SS disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.126_129del (p.Phe42fs) AND Fetal hemoglobin quantitative trait locus 1" Accession="RCV001262999" Version="9">
        <ClassifiedConditionList TraitSetID="6347">
          <ClassifiedCondition DB="MedGen" ID="C1841621">Fetal hemoglobin quantitative trait locus 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-01-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.126_129del (p.Phe42fs) AND Beta-thalassemia HBB/LCRB" Accession="RCV002465488" Version="12">
        <ClassifiedConditionList TraitSetID="80504">
          <ClassifiedCondition DB="MedGen" ID="CN322236">Beta-thalassemia HBB/LCRB</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2021-11-04" SubmissionCount="3">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.126_129del (p.Phe42fs) AND Inborn genetic diseases" Accession="RCV002426507" Version="9">
        <ClassifiedConditionList TraitSetID="25797">
          <ClassifiedCondition DB="MedGen" ID="C0950123">Inborn genetic diseases</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2015-11-25" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.126_129del (p.Phe42fs) AND multiple conditions" Accession="RCV002496380" Version="8">
        <ClassifiedConditionList TraitSetID="82018">
          <ClassifiedCondition DB="MedGen" ID="CN322236">Beta-thalassemia HBB/LCRB</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1858990">Dominant beta-thalassemia</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C4693822">Erythrocytosis, familial, 6</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0002895">Hb SS disease</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0700299">Heinz body anemia</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0019025">Hereditary persistence of fetal hemoglobin</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1840779">METHEMOGLOBINEMIA, BETA TYPE</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1970028">Malaria, susceptibility to</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0002312">alpha Thalassemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-03-08" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.126_129del (p.Phe42fs) AND HBB-related disorder" Accession="RCV004532368" Version="1">
        <ClassifiedConditionList TraitSetID="33481">
          <ClassifiedCondition DB="MedGen" ID="CN239378">HBB-related disorder</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-01-09" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-01-31" NumberOfSubmissions="22" NumberOfSubmitters="22" DateCreated="2017-03-22" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <CitationText>Kazazian, H. H., Jr. Personal Communication. 1982. Baltimore, Md.</CitationText>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12000828</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12383672</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15181845</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20181291</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22188014</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23637309</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24200214</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25000193</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25089872</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25135424</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25480500</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25849334</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26290351</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26291967</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28635337</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29484903</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">6714226</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">6826539</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8435318</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9113933</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9845707</ID>
        </Citation>
        <Citation Type="general">
          <URL>https://ithanet.eu/db/ithagenes?ithaID=147</URL>
        </Citation>
        <Citation Type="review" Abbrev="GeneReviews">
          <ID Source="PubMed">20301599</ID>
          <ID Source="BookShelf">NBK1426</ID>
        </Citation>
        <DescriptionHistory Dated="2019-05-24">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="4683" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="11956" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Beta zero thalassemia</ElementValue>
                <XRef ID="86715000" DB="SNOMED CT" />
              </Name>
              <Citation Type="practice guideline" Abbrev="ACMG ACT Sheet, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Anemia-HBss.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Sickle Cell Anemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-EE-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, FE, Hemoglobin EE or Hemoglobin E/Beta Zero Thalassemia (Hb EE or Hb E/ß0 Disease), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Beta-Thalassemia-Major-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Hemoglobin F-Only; Hemoglobin F With Decreased A, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-FS-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, FS: Hemoglobin S Screening Result, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Beta-Thalassemia-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin F Only or F with Decreased A: Transfusion Dependent or Non Transfusion Dependent beta-Thalassemia; Hb beta 0 Thalassemia; Hb beta+/beta+ Thalassemia; Hb beta0/beta+ Thalassemia Screening Result, 2023</CitationText>
              </Citation>
              <XRef ID="C0271980" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="33481" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="36575" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">HBB-Related Disorders</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">HBB-related condition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">HBB-related disorder</ElementValue>
              </Name>
              <XRef ID="CN239378" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="80504" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="65989" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Beta-thalassemia HBB/LCRB</ElementValue>
                <XRef ID="MONDO:0013517" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Beta-thalassemia (β-thalassemia) is characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis. Individuals with thalassemia major have severe anemia and hepatosplenomegaly; they usually come to medical attention within the first two years of life. Without treatment, affected children have severe failure to thrive and shortened life expectancy. Treatment with a regular transfusion program and chelation therapy, aimed at reducing transfusion iron overload, allows for normal growth and development and may improve the overall prognosis. Individuals with thalassemia intermedia present later and have milder anemia that does not require regular treatment with blood transfusion. These individuals are at risk for iron overload secondary to increased intestinal absorption of iron as a result of ineffective erythropoiesis.</Attribute>
                <XRef ID="NBK1426" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301599</ID>
                <ID Source="BookShelf">NBK1426</ID>
              </Citation>
              <XRef ID="CN322236" DB="MedGen" />
              <XRef ID="MONDO:0013517" DB="MONDO" />
              <XRef Type="MIM" ID="613985" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="6347" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1808" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Fetal hemoglobin quantitative trait locus 1</ElementValue>
                <XRef ID="Fetal+hemoglobin+quantitative+trait+locus+1/8427" DB="Genetic Alliance" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">HBFQTL1</ElementValue>
                <XRef Type="MIM" ID="141749" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary Persistence of Fetal Hemoglobin</Attribute>
              </AttributeSet>
              <XRef ID="251380" DB="Orphanet" />
              <XRef ID="C1841621" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="25797" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="32761" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Inborn genetic diseases</ElementValue>
              </Name>
              <Citation Type="general" Abbrev="Langer et al., 2012">
                <ID Source="PubMed">22947299</ID>
              </Citation>
              <Citation Type="general" Abbrev="SACHDNC, 2013">
                <ID Source="PubMed">23037933</ID>
              </Citation>
              <Citation Type="general" Abbrev="EASAC/FEAM, 2013">
                <ID Source="PubMed">23169492</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESHG/P3G/HUGO/PHGF, 2015">
                <ID Source="PubMed">25626707</ID>
              </Citation>
              <Citation Type="general" Abbrev="Alpha-1 Foundation, 2014">
                <ID Source="PubMed">24121147</ID>
              </Citation>
              <Citation Type="general" Abbrev="NBSTRN, 2015">
                <ID Source="PubMed">24394680</ID>
              </Citation>
              <Citation Type="general" Abbrev="EUNENBS, 2014">
                <ID Source="PubMed">23652378</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2014">
                <ID Source="PubMed">23881473</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/ACOG/NSGC/PQF/SMFM, 2015">
                <ID Source="PubMed">25730230</ID>
              </Citation>
              <Citation Type="general" Abbrev="Skirton et al., 2014">
                <ID Source="PubMed">24022298</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23619275</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2019">
                <ID Source="PubMed">31022120</ID>
              </Citation>
              <XRef ID="C0950123" DB="MedGen" />
              <XRef ID="D030342" DB="MeSH" />
            </Trait>
          </TraitSet>
          <TraitSet ID="82018" Type="TraitChoice" ContributesToAggregateClassification="true">
            <Trait ID="40028" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">ERYTHROCYTOSIS, BETA-GLOBIN TYPE</ElementValue>
                <XRef Type="MIM" ID="617980" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">POLYCYTHEMIA, BETA-GLOBIN TYPE</ElementValue>
                <XRef Type="MIM" ID="617980" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Erythrocytosis, familial, 6</ElementValue>
                <XRef ID="MONDO:0054801" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">ECYT6</ElementValue>
                <XRef Type="MIM" ID="617980" DB="OMIM" />
              </Symbol>
              <XRef ID="C4693822" DB="MedGen" />
              <XRef ID="MONDO:0054801" DB="MONDO" />
              <XRef Type="MIM" ID="617980" DB="OMIM" />
            </Trait>
            <Trait ID="16291" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">METHEMOGLOBINEMIA, BETA TYPE</ElementValue>
                <XRef Type="MIM" ID="617971" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141900.0163" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141900.0164" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Methemoglobinemia, beta-globin type</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="13007" />
                <XRef ID="13007" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="C1840779" DB="MedGen" />
              <XRef Type="MIM" ID="617971" DB="OMIM" />
            </Trait>
            <Trait ID="65989" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Beta-thalassemia HBB/LCRB</ElementValue>
                <XRef ID="MONDO:0013517" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Beta-thalassemia (β-thalassemia) is characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis. Individuals with thalassemia major have severe anemia and hepatosplenomegaly; they usually come to medical attention within the first two years of life. Without treatment, affected children have severe failure to thrive and shortened life expectancy. Treatment with a regular transfusion program and chelation therapy, aimed at reducing transfusion iron overload, allows for normal growth and development and may improve the overall prognosis. Individuals with thalassemia intermedia present later and have milder anemia that does not require regular treatment with blood transfusion. These individuals are at risk for iron overload secondary to increased intestinal absorption of iron as a result of ineffective erythropoiesis.</Attribute>
                <XRef ID="NBK1426" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301599</ID>
                <ID Source="BookShelf">NBK1426</ID>
              </Citation>
              <XRef ID="CN322236" DB="MedGen" />
              <XRef ID="MONDO:0013517" DB="MONDO" />
              <XRef Type="MIM" ID="613985" DB="OMIM" />
            </Trait>
            <Trait ID="5915" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Sickle cell anemia</ElementValue>
                <XRef ID="MONDO:0011382" DB="MONDO" />
                <XRef ID="232" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hb SS disease</ElementValue>
                <XRef ID="127040003" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sickle cell disease</ElementValue>
                <XRef ID="C34383" DB="NCI" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">HbS disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hemoglobin S Disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sickling disorder due to hemoglobin S</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">SCD</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8614" />
                <XRef ID="8614" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Sickle cell disease (SCD) is characterized by intermittent vaso-occlusive events and chronic hemolytic anemia. Vaso-occlusive events result in tissue ischemia leading to acute and chronic pain as well as organ damage that can affect any organ system, including the bones, spleen, liver, brain, lungs, kidneys, and joints. Dactylitis (pain and/or swelling of the hands or feet) is often the earliest manifestation of SCD. In children, the spleen can become engorged with blood cells in a "splenic sequestration." The spleen is particularly vulnerable to infarction and the majority of individuals with SCD who are not on hydroxyurea or transfusion therapy become functionally asplenic in early childhood, increasing their risk for certain types of bacterial infections, primarily encapsulated organisms. Acute chest syndrome (ACS) is a major cause of mortality in SCD. Chronic hemolysis can result in varying degrees of anemia, jaundice, cholelithiasis, and delayed growth and sexual maturation as well as activating pathways that contribute to the pathophysiology directly. Individuals with the highest rates of hemolysis are at higher risk for pulmonary artery hypertension, priapism, and leg ulcers and may be relatively protected from vaso-occlusive pain.</Attribute>
                <XRef ID="NBK1377" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301551</ID>
                <ID Source="BookShelf">NBK1377</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2009">
                <ID Source="PubMed">19323364</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2006">
                <ID Source="pmc">3111605</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT Sheet, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Anemia-HBss.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Sickle Cell Anemia, 2023</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="Yawn et al., 2014">
                <ID Source="PubMed">25203083</ID>
              </Citation>
              <Citation Type="general" Abbrev="AHA/ASA, 2014">
                <ID Source="PubMed">25355838</ID>
              </Citation>
              <Citation Type="general" Abbrev="EMQN, 2014">
                <ID Source="PubMed">25052315</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Carrier-NBS-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Newborn Screening ACT Sheet, [FAS] Sickle Cell Carrier (HbAS)</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2021">
                <ID Source="PubMed">17197616</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-S-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb S Screening, 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Carrier-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Carrier Screening ACT Sheet, Sickle Cell Carrier/Trait, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Disease-Transition.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Transition to Adult Health Care ACT Sheet, Sickle Cell Disease, 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-FS-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, FS: Hemoglobin S Screening Result, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-AS-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, FAS: Sickle Cell Trait Screening Result, 2023</CitationText>
              </Citation>
              <XRef ID="232" DB="Orphanet" />
              <XRef ID="C0002895" DB="MedGen" />
              <XRef ID="MONDO:0011382" DB="MONDO" />
              <XRef Type="MIM" ID="603903" DB="OMIM" />
            </Trait>
            <Trait ID="5228" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Heinz body anemias</ElementValue>
                <XRef ID="Heinz+body+anemias/3265" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Heinz body hemolytic anemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Heinz body anemia</ElementValue>
                <XRef ID="HP:0005511" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0007705" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10718" />
                <XRef ID="10718" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="178330" DB="Orphanet" />
              <XRef ID="C0700299" DB="MedGen" />
              <XRef ID="MONDO:0007705" DB="MONDO" />
              <XRef Type="MIM" ID="140700" DB="OMIM" />
              <XRef Type="primary" ID="HP:0005511" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="55601" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Hereditary persistence of fetal hemoglobin</ElementValue>
                <XRef ID="319672" DB="GeneTests" />
                <XRef ID="MONDO:0020989" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">HPFH</ElementValue>
                <XRef Type="MIM" ID="141749" DB="OMIM" />
              </Symbol>
              <Citation Type="practice guideline" Abbrev="ACMG ACT Sheet, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Anemia-HBss.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Sickle Cell Anemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Beta-Thalassemia-Major-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Hemoglobin F-Only; Hemoglobin F With Decreased A, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-FS-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, FS: Hemoglobin S Screening Result, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Beta-Thalassemia-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin F Only or F with Decreased A: Transfusion Dependent or Non Transfusion Dependent beta-Thalassemia; Hb beta 0 Thalassemia; Hb beta+/beta+ Thalassemia; Hb beta0/beta+ Thalassemia Screening Result, 2023</CitationText>
              </Citation>
              <XRef ID="C0019025" DB="MedGen" />
              <XRef ID="MONDO:0020989" DB="MONDO" />
              <XRef Type="MIM" ID="141749" DB="OMIM" />
            </Trait>
            <Trait ID="10300" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Malaria, susceptibility to</ElementValue>
                <XRef ID="MONDO:0021024" DB="MONDO" />
              </Name>
              <XRef ID="673" DB="Orphanet" />
              <XRef ID="C1970028" DB="MedGen" />
              <XRef ID="MONDO:0021024" DB="MONDO" />
              <XRef Type="MIM" ID="611162" DB="OMIM" />
            </Trait>
            <Trait ID="6489" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">A-Thalassemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">alpha Thalassemia</ElementValue>
                <XRef ID="Alpha-Thalassemia/333" DB="Genetic Alliance" />
                <XRef ID="68913001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpha thalassemia spectrum</ElementValue>
                <XRef ID="MONDO:0011399" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Alpha-thalassemia (α-thalassemia) has two clinically significant forms: hemoglobin Bart hydrops fetalis (Hb Bart) syndrome (caused by deletion/inactivation of all four α-globin genes; --/--), and hemoglobin H (HbH) disease (most frequently caused by deletion/inactivation of three α-globin genes; --/-α). Hb Bart syndrome, the more severe form, is characterized by prenatal onset of generalized edema and pleural and pericardial effusions as a result of congestive heart failure induced by severe anemia. Extramedullary erythropoiesis, marked hepatosplenomegaly, and a massive placenta are common. Death usually occurs in the neonatal period. HbH disease has a broad phenotypic spectrum: although clinical features usually develop in the first years of life, HbH disease may not present until adulthood or may be diagnosed only during routine hematologic analysis in an asymptomatic individual. The majority of individuals have enlargement of the spleen (and less commonly of the liver), mild jaundice, and sometimes thalassemia-like bone changes. Individuals with HbH disease may develop gallstones and experience acute episodes of hemolysis in response to infections or exposure to oxidant drugs.</Attribute>
                <XRef ID="NBK1435" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="621" />
                <XRef ID="621" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301608</ID>
                <ID Source="BookShelf">NBK1435</ID>
              </Citation>
              <Citation Type="general" Abbrev="EMQN, 2014">
                <ID Source="PubMed">25052315</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2021">
                <ID Source="PubMed">17197616</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, FA + Barts Hb, Alpha (a) Thalassemia, 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics Newborn Screening ACT sheet, FA + Barts present (unquantified), FAB, Alpha Thalassemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Unquantified Barts Alpha Thalassemia Screening Result (FAB), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Low/Moderate Barts Alpha Thalassemia Screening Result (FAB2; FAB1), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-ACT-Sheet.pdf</URL>
                <CitationText>ACMG ACT, FA + Low/Moderate Barts Hb, FAB2, FAB1 Alpha Thalassemia: Silent carrier and alpha thalassemia trait, 2023</CitationText>
              </Citation>
              <XRef ID="846" DB="Orphanet" />
              <XRef ID="C0002312" DB="MedGen" />
              <XRef ID="MONDO:0011399" DB="MONDO" />
              <XRef Type="MIM" ID="604131" DB="OMIM" />
            </Trait>
            <Trait ID="383" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">DYSERYTHROPOIETIC ANEMIA, CONGENITAL, IRISH OR WEATHERALL TYPE</ElementValue>
                <XRef Type="MIM" ID="603902" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Beta-thalassemia, dominant inclusion body type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Dominant beta-thalassemia</ElementValue>
                <XRef ID="MONDO:0011381" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">D-BTHAL</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17164" />
                <XRef ID="17164" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="231226" DB="Orphanet" />
              <XRef ID="848" DB="Orphanet" />
              <XRef ID="C1858990" DB="MedGen" />
              <XRef ID="MONDO:0011381" DB="MONDO" />
              <XRef Type="MIM" ID="603902" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="4697" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="11970" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Cooley's anemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Erythroblastic anemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mediterranean anemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">beta Thalassemia</ElementValue>
                <XRef ID="Beta+Thalassemia/814" DB="Genetic Alliance" />
                <XRef ID="65959000" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">BTHAL</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Beta-thalassemia (β-thalassemia) is characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis. Individuals with thalassemia major have severe anemia and hepatosplenomegaly; they usually come to medical attention within the first two years of life. Without treatment, affected children have severe failure to thrive and shortened life expectancy. Treatment with a regular transfusion program and chelation therapy, aimed at reducing transfusion iron overload, allows for normal growth and development and may improve the overall prognosis. Individuals with thalassemia intermedia present later and have milder anemia that does not require regular treatment with blood transfusion. These individuals are at risk for iron overload secondary to increased intestinal absorption of iron as a result of ineffective erythropoiesis.</Attribute>
                <XRef ID="NBK1426" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="871" />
                <XRef ID="871" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000515560" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520044" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592289" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592332" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000567333" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591289" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522527" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520115" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000596318" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000260581" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000556525" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000529085" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592333" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592286" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501908" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501909" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508856" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000556526" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521590" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558937" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570317" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501386" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592287" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301599</ID>
                <ID Source="BookShelf">NBK1426</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2021">
                <ID Source="PubMed">17197616</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Beta-Thalassemia-Major-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Hemoglobin F-Only; Hemoglobin F With Decreased A, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-E-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, FEA, Hemoglobin E/Beta Plus Thalassemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Beta-Thalassemia-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin F Only or F with Decreased A: Transfusion Dependent or Non Transfusion Dependent beta-Thalassemia; Hb beta 0 Thalassemia; Hb beta+/beta+ Thalassemia; Hb beta0/beta+ Thalassemia Screening Result, 2023</CitationText>
              </Citation>
              <XRef ID="848" DB="Orphanet" />
              <XRef ID="C0005283" DB="MedGen" />
              <XRef ID="MONDO:0019402" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="4606" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5915" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Sickle cell anemia</ElementValue>
                <XRef ID="MONDO:0011382" DB="MONDO" />
                <XRef ID="232" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hb SS disease</ElementValue>
                <XRef ID="127040003" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sickle cell disease</ElementValue>
                <XRef ID="C34383" DB="NCI" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">HbS disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hemoglobin S Disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sickling disorder due to hemoglobin S</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">SCD</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8614" />
                <XRef ID="8614" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Sickle cell disease (SCD) is characterized by intermittent vaso-occlusive events and chronic hemolytic anemia. Vaso-occlusive events result in tissue ischemia leading to acute and chronic pain as well as organ damage that can affect any organ system, including the bones, spleen, liver, brain, lungs, kidneys, and joints. Dactylitis (pain and/or swelling of the hands or feet) is often the earliest manifestation of SCD. In children, the spleen can become engorged with blood cells in a "splenic sequestration." The spleen is particularly vulnerable to infarction and the majority of individuals with SCD who are not on hydroxyurea or transfusion therapy become functionally asplenic in early childhood, increasing their risk for certain types of bacterial infections, primarily encapsulated organisms. Acute chest syndrome (ACS) is a major cause of mortality in SCD. Chronic hemolysis can result in varying degrees of anemia, jaundice, cholelithiasis, and delayed growth and sexual maturation as well as activating pathways that contribute to the pathophysiology directly. Individuals with the highest rates of hemolysis are at higher risk for pulmonary artery hypertension, priapism, and leg ulcers and may be relatively protected from vaso-occlusive pain.</Attribute>
                <XRef ID="NBK1377" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301551</ID>
                <ID Source="BookShelf">NBK1377</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2009">
                <ID Source="PubMed">19323364</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2006">
                <ID Source="pmc">3111605</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT Sheet, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Anemia-HBss.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Sickle Cell Anemia, 2023</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="Yawn et al., 2014">
                <ID Source="PubMed">25203083</ID>
              </Citation>
              <Citation Type="general" Abbrev="AHA/ASA, 2014">
                <ID Source="PubMed">25355838</ID>
              </Citation>
              <Citation Type="general" Abbrev="EMQN, 2014">
                <ID Source="PubMed">25052315</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Carrier-NBS-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Newborn Screening ACT Sheet, [FAS] Sickle Cell Carrier (HbAS)</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2021">
                <ID Source="PubMed">17197616</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-S-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb S Screening, 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Carrier-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Carrier Screening ACT Sheet, Sickle Cell Carrier/Trait, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Disease-Transition.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Transition to Adult Health Care ACT Sheet, Sickle Cell Disease, 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-FS-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, FS: Hemoglobin S Screening Result, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-AS-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, FAS: Sickle Cell Trait Screening Result, 2023</CitationText>
              </Citation>
              <XRef ID="232" DB="Orphanet" />
              <XRef ID="C0002895" DB="MedGen" />
              <XRef ID="MONDO:0011382" DB="MONDO" />
              <XRef Type="MIM" ID="603903" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1190083" SubmissionDate="2017-10-05" DateLastUpdated="2017-09-30" DateCreated="2017-09-30">
        <ClinVarSubmissionID localKey="35818965" />
        <ClinVarAccession Accession="SCV000610030" DateUpdated="2017-09-30" DateCreated="2017-09-30" Type="SCV" Version="1" SubmitterName="Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics" OrgID="505698" OrganizationCategory="clinic" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-03-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>Homo sapiens</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <NamePlatform>Illumina</NamePlatform>
              <TypePlatform>Sequencing</TypePlatform>
              <ResultType>variant call</ResultType>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="AlleleFrequency">0.000208</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Deletion</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="11" Strand="+" alternateAllele="-" referenceAllele="AAAG" start="5247993" stop="5247996" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1363428" SubmissionDate="2018-01-25" DateLastUpdated="2017-03-22" DateCreated="2017-03-22">
        <ClinVarSubmissionID localKey="NM_000518.4:c.126_129delCTTT|MedGen:C0005283" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000697076" DateUpdated="2017-03-22" DateCreated="2017-03-22" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-04-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">8435318</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15181845</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">6714226</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9113933</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25089872</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">6826539</ID>
          </Citation>
          <Comment>Variant summary: The c.126_129delCTTT variant results in a premature termination codon, predicted to cause a truncated or absent HBB protein, which is a commonly known mechanism for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g.c.135delC, c.143_146dupATCT). Mutation taster predicts damaging outcome for this variant. This variant is found in 33/121370 control chromosomes at a frequency of 0.0002719, which does not exceed maximal expected frequency of a pathogenic allele (0.0111803). This variant is reported in the literatures as a well-known pathogenic variant predominantly identified in East and South Asian. In addition, multiple reputable databases classified this variant as pathogenic. Taken together, this variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
            <CitationText>LabCorp Variant Classification Summary - May 2015.docx</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <XRefList>
            <XRef DB="dbSNP" ID="80356821" Type="rsNumber" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.126_129delCTTT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0005283" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2016-2017-variants</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="36943" SubmissionDate="2017-12-12" DateLastUpdated="2018-05-09" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="141900.0326_BETA-ZERO-THALASSEMIA" title="HBB, 4-BP DEL, 41/42CTTT_BETA-ZERO-THALASSEMIA" />
        <ClinVarAccession Accession="SCV000036943" DateUpdated="2018-05-09" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2002-09-28">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Frameshift, -4, codons 41/42, TTCTTT to TT, was found in an Asian Indian with beta-zero-thalassemia (613985) by Kazazian et al. (1984) and in Chinese by Kimura et al. (1983).</Attribute>
              <Citation>
                <CitationText>Kazazian, H. H., Jr. Personal Communication. 1982. Baltimore, Md.</CitationText>
              </Citation>
              <Citation>
                <ID Source="PubMed">6826539</ID>
              </Citation>
              <XRef DB="OMIM" ID="613985" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Lau et al. (1997) found that the deletion of CTTT at codons 41/42 accounted for 40% of all beta-thalassemia alleles in Hong Kong. Chiu et al. (2002) designed allele-specific primers and a fluorescent probe for detection of this mutation in the HBB gene from maternal plasma by real-time PCR. Using this method, they showed that beta-thalassemia major could be excluded from fetal inheritance by demonstrating absence of inheritance of the paternally transmitted mutation. By studying circulating fetal DNA in the maternal plasma for this mutation, Chiu et al. (2002) added beta-thalassemia to the list of disorders that could be prenatally diagnosed using this noninvasive method, which had previously demonstrated usefulness in diagnosing sex-linked diseases (Costa et al., 2002) and fetal rhesus D status (Lo et al., 1998).</Attribute>
              <Citation>
                <ID Source="PubMed">9113933</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">12383672</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">12000828</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">9845707</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <Name>HBB, 4-BP DEL, 41/42CTTT</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">4-BP DEL, 41/42CTTT</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="141900.0326" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">BETA-ZERO-THALASSEMIA</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1789583" SubmissionDate="2019-02-01" DateLastUpdated="2019-05-27" DateCreated="2019-05-27">
        <ClinVarSubmissionID localKey="702068" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000914517" DateUpdated="2019-05-27" DateCreated="2019-05-27" Type="SCV" Version="1" SubmitterName="Illumina Laboratory Services, Illumina" OrgID="504895" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-10-31">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">24200214</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26290351</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25000193</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25135424</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25849334</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22188014</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">6826539</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20301599</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26291967</ID>
          </Citation>
          <Comment>The HBB c.126_129delCTTT (p.Phe42LeufsTer19) variant, also described as codon 41/42 (-CTTT) or codon 41/42 (-TTCT), results in a frameshift and is predicted to result in premature truncation of the protein. This variant is particularly prevalent in the Chinese population and is usually associated with a beta-thalassemia phenotype (Lin et al. 2014; Zhang et al. 2015; Yu et al. 2015; Origa et al 2015). Across a selection of the available literature, the p.Phe42LeufsTer19 variant has been identified in a homozygous state in one individual and in a compound heterozygous state in seven individuals, all with beta-thalassemia (Kimura et al. 1983; Hernanda et al. 2012; Huang et al. 2014; Italia et al. 2015; Rujito et al. 2015). Control data are unavailable for this variant, which is reported at a frequency of 0.00496 in the East Asian population of the 1000 Genomes. Based on the evidence and the potential impact of frameshift variants, the p.Phe42LeufsTer19 variant is interpreted as pathogenic for beta-thalassemia. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ICSL Variant Classification Criteria 09 May 2019</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/thsgk7t4/icsl_variant_classification_criteria_09_may_2019.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="11" alternateAllele="C" referenceAllele="CAAAG" start="5247992" stop="5247996" variantLength="5" />
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.126_129delCTTT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613985" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5118208</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2292709" SubmissionDate="2019-09-27" DateLastUpdated="2020-02-29" DateCreated="2020-02-29">
        <ClinVarSubmissionID localKey="NC_000011.9:g.5247995_5247998delAGAA|OMIM:603903" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001163653" DateUpdated="2020-02-29" DateCreated="2020-02-29" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.9:g.5247995_5247998delAGAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603903" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>BG_GA_2018_SNVs_INDELS</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2454031" SubmissionDate="2019-11-25" DateLastUpdated="2020-04-24" DateCreated="2020-04-24">
        <ClinVarSubmissionID localKey="ithaID:147|Orphanet:ORPHA:848" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV001244545" DateUpdated="2020-04-24" DateCreated="2020-04-24" Type="SCV" Version="1" SubmitterName="The ITHANET community portal, The Cyprus Institute of Neurology and Genetics" OrgID="507248" OrganizationCategory="locus-specific database (LSDB)" OrgAbbreviation="ITHANET" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-11-25">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">6714226</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">6826539</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29484903</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>CD 41/42 (-CTTT)</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="141900.0326" Type="Allelic variant" />
            <XRef DB="dbSNP" ID="281864900" Type="rsNumber" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.126_129del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">beta Thalassemia</ElementValue>
            </Name>
            <XRef DB="Orphanet" ID="ORPHA848" />
          </Trait>
        </TraitSet>
        <Citation>
          <URL>https://ithanet.eu/db/ithagenes?ithaID=147</URL>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB6599191</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2354485" SubmissionDate="2020-06-18" DateLastUpdated="2020-07-06" DateCreated="2020-04-06">
        <ClinVarSubmissionID localKey="62|OMIM:613985" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001194030" DateUpdated="2020-07-06" DateCreated="2020-04-06" Type="SCV" Version="2" SubmitterName="Myriad Genetics, Inc." OrgID="507240" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <ReplacedList>
          <Replaced Accession="SCV000678184" DateChanged="2020-07-02" Version="2">
            <Comment Type="MergeComment">SCV000678184 was merged into SCV001194030 to remove duplication.</Comment>
          </Replaced>
        </ReplacedList>
        <Classification DateLastEvaluated="2019-12-09">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">6826539</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25000193</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">6714226</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25480500</ID>
          </Citation>
          <Comment>NM_000518.4(HBB):c.126_129delCTTT(F42Lfs*19) is classified as pathogenic in the context of Hb beta chain-related hemoglobinopathy; it is associated with beta thalassemia and is classified as a beta-zero variant. Sources cited for classification include the following: PMID 6826539, 25000193, 6714226 and 25480500. Classification of NM_000518.4(HBB):c.126_129delCTTT(F42Lfs*19) is based on the following criteria: The variant causes a premature termination codon that is expected to be targeted by nonsense-mediated mRNA decay and is reported in individuals with the relevant phenotype. Please note: this variant was assessed in the context of healthy population screening.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Myriad Women's Health Autosomal Recessive and X-Linked Classification Criteria (2019)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/vlxza0ea/myriad_women_s_health_autosomal_recessive_and_x-linked_classification_criteria_2019_.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="11" alternateAllele="C" referenceAllele="CAAAG" start="5247992" stop="5247996" variantLength="5" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613985" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6849778</SubmissionName>
          <SubmissionName>SUB7605676</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2844131" SubmissionDate="2020-10-12" DateLastUpdated="2020-10-31" DateCreated="2020-10-31">
        <ClinVarSubmissionID localKey="CV_varv_576|OMIM:141749" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001441069" DateUpdated="2020-10-31" DateCreated="2020-10-31" Type="SCV" Version="1" SubmitterName="Institute of Human Genetics, University of Leipzig Medical Center" OrgID="506086" OrganizationCategory="clinic" OrgAbbreviation="UKL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-01-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>no</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.126_129del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="141749" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>varv_082020</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1164935" SubmissionDate="2017-08-01" DateLastUpdated="2022-01-03" DateCreated="2017-09-30">
        <ClinVarSubmissionID localKey="NM_000518.4:c.126_129del|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000601240" DateUpdated="2022-01-03" DateCreated="2017-09-30" Type="SCV" Version="2" SubmitterName="Quest Diagnostics Nichols Institute San Juan Capistrano" OrgID="500110" OrganizationCategory="laboratory" OrgAbbreviation="Quest Diagnostics" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-11-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">6826539</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">6714226</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24200214</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Quest Diagnostics criteria</Attribute>
          <Citation>
            <ID Source="PubMed">26467025</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>p.Phe42Leufs*19</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.126_129del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB2915479</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4083830" SubmissionDate="2022-02-09" DateLastUpdated="2022-04-23" DateCreated="2022-04-23">
        <ClinVarSubmissionID localKey="NM_000518.5:c.126_129del|Beta thalassemia" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002089222" DateUpdated="2022-04-23" DateCreated="2022-04-23" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-03-17">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.126_129del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Beta thalassemia</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10993736</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="40704" SubmissionDate="2022-04-01" DateLastUpdated="2022-10-01" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="NM_000518.4:c.124_127delTTCT|OMIM:613985" submittedAssembly="not applicable" />
        <ClinVarAccession Accession="SCV000040704" DateUpdated="2022-10-01" DateCreated="2013-04-04" Type="SCV" Version="4" SubmitterName="GeneReviews" OrgID="500062" OrganizationCategory="resource" OrgAbbreviation="GeneReviews" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no classification provided</ReviewStatus>
          <GermlineClassification>not provided</GermlineClassification>
          <Citation>
            <ID Source="BookShelf">NBK1426</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.124_127delTTCT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0005283" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11264553</SubmissionName>
          <SubmissionName>SUB11808016</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5002466" SubmissionDate="2022-12-11" DateLastUpdated="2022-12-17" DateCreated="2022-08-08">
        <ClinVarSubmissionID localKey="sa_pathology/genomics_unit/vc23072" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002556512" DateUpdated="2022-12-17" DateCreated="2022-08-08" Type="SCV" Version="2" SubmitterName="Genetics and Molecular Pathology, SA Pathology" OrgID="506043" OrganizationCategory="laboratory" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="508197" SubmitterName="Shariant Australia, Australian Genomics" Type="behalf" OrganizationCategory="consortium" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">ALLELE_1959</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.126_129delCTTT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613985" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>submission_33</SubmissionName>
          <SubmissionName>submission_36</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5459364" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_000518.5:c.126_129del|OMIM:140700;141749;603902;603903;604131;611162;613985;617971;617980" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002813078" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-03-08">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.126_129del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="140700" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="141749" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603902" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603903" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="604131" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="611162" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613985" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="617971" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="617980" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1457141" SubmissionDate="2021-11-03" DateLastUpdated="2023-03-04" DateCreated="2017-09-30">
        <ClinVarSubmissionID localKey="GDXSV:208720" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV000748427" DateUpdated="2023-03-04" DateCreated="2017-09-30" Type="SCV" Version="5" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 20181291, 22975760, 6826539, 11224481, 24200214, 28635337, 26096776, 30487145, 30945812, 31111750, 31930713, 30275481, 10870880, 33198537, 8091935)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:691140</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.126_129del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_69_20211103203310</SubmissionName>
          <SubmissionName>SUB5098196</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7574095" SubmissionDate="2023-10-19" DateLastUpdated="2023-10-28" DateCreated="2023-10-28">
        <ClinVarSubmissionID localKey="11100126961_1" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004047359" DateUpdated="2023-10-28" DateCreated="2023-10-28" Type="SCV" Version="1" SubmitterName="Neuberg Centre For Genomic Medicine, NCGM" OrgID="508108" OrganizationCategory="laboratory" OrgAbbreviation="NCGM" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant c.126_129del (p.Phe42LeufsTer19) in HBB gene has been observed in the homozygous and compound heterozygous state in several individuals with HBB-related conditions (Kimura A et al., 1983). This sequence change creates a premature translational stop signal (p.Phe42Leufs*19) in the HBB gene. It is expected to result in an absent or disrupted protein product. This variant is present in the gnomAD database with a frequency of 0.03%. Loss-of-function variants in HBB are known to be pathogenic (Craig JE et al., 1994). This variant has been reported to the ClinVar database as Pathogenic. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0005561" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0000421" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0001915" />
              </Trait>
              <Comment>6 years old female born of non-consanguineous marriage was referred for genetic evaluation. Clinical details- bleeding gums; epistaxis; leg pain; ecchymosis; wet purpura Diagnosis- Aplastic anemia; hemoglobinopathy Clinical suspicion- bone marrow failure syndrome.</Comment>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.126_129del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613985" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13901154</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2282362" SubmissionDate="2024-01-24" DateLastUpdated="2024-02-20" DateCreated="2020-02-10">
        <ClinVarSubmissionID localKey="2199150|MedGen:CN235283" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001157958" DateUpdated="2024-02-20" DateCreated="2020-02-10" Type="SCV" Version="8" SubmitterName="ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories" OrgID="25969" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-11-21">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The HBB c.126_129del; p.Phe42LeufsTer19 variant (also known as Phe41fs when numbered from the mature protein or as codon 41/42-TTCT, rs80356821, HbVar ID: 849) has been reported in the homozygous and compound heterozygous states in individuals affected with beta(0) thalassemia (see link to HbVar, Kimura 1983). It is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 15417) and is observed in the general population at an overall frequency of 0.02% (73/282786 alleles) with increased frequency in the East Asian population (0.2%) in the Genome Aggregation Database. This variant creates a frameshift by deleting 4 nucleotides, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic. References: Link to HbVar: https://globin.bx.psu.edu/hbvar/hbvar.html Kimura A et al. Structural analysis of a beta-thalassemia gene found in Taiwan. J Biol Chem. 1983 Mar 10;258(5):2748-9. PMID: 6826539.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ARUP Molecular Germline Variant Investigation Process 2024</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/xwiqgyug/arup_molecular_germline_variant_investigation_process_arup-info-0022_2024.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.9:g.5247995_5247998del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN235283" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2020 ARUP</SubmissionName>
          <SubmissionName>2022 ARUP ClinVar submission</SubmissionName>
          <SubmissionName>2023 ARUP ClinVar submission</SubmissionName>
          <SubmissionName>ARUP Molecular 2021</SubmissionName>
          <SubmissionName>May 2022</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5164797" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2022-11-29">
        <ClinVarSubmissionID localKey="a9244|MedGen:C0950123" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002677342" DateUpdated="2024-05-01" DateCreated="2022-11-29" Type="SCV" Version="2" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-11-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">6826539</ID>
          </Citation>
          <Comment>The c.126_129delCTTT pathogenic mutation (also known as codons 41/42 (-TTCT) and c.124_127delTTCT), located in coding exon 2 of the HBB gene, results from a deletion of 4 nucleotides between positions 126 and 129, causing a translational frameshift with a predicted alternate stop codon (p.F42Lfs*19). This mutation is associated with beta0-thalassemia and was originally reported as homozygous in a Chinese patient (Kimura A et al. J Biol Chem. 1983;258(5):2748-9). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.126_129delCTTT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0950123" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2862763" SubmissionDate="2020-11-26" DateLastUpdated="2020-12-12" DateCreated="2020-12-12">
        <ClinVarSubmissionID localKey="NM_000518.5:c.126_129del|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001449897" DateUpdated="2020-12-12" DateCreated="2020-12-12" Type="SCV" Version="1" SubmitterName="Clinical Genetics and Genomics, Karolinska University Hospital" OrgID="505315" OrganizationCategory="laboratory" OrgAbbreviation="KLINGEN-KUS" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-08-29">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="2" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.126_129del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8639822</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7193227" SubmissionDate="2023-03-30" DateLastUpdated="2023-04-01" DateCreated="2023-04-01">
        <ClinVarSubmissionID localKey="SUB13006849" submittedAssembly="hg19" title="SUB13006849" />
        <ClinVarAccession Accession="SCV003845971" DateUpdated="2023-04-01" DateCreated="2023-04-01" Type="SCV" Version="1" SubmitterName="Lifecell International Pvt. Ltd" OrgID="507720" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation Type="general">
            <ID Source="PubMed">20181291</ID>
          </Citation>
          <Comment>A Heterozygous Frameshift variant c.126_129delCTTT in Exon 2 of the HBB gene that results in the premature termination of the protein (p.Phe42fs*19) was identified. The observed variant has a minor allele frequency of 0.00028% in gnomAD exomes and genomes, respectively. The severity of the impact of this variant on the protein is high, based on the effect ofthe protein and REVEL score . Rare Exome Variant Ensemble Learner (REVEL) is an ensembl method for predicting the pathogenicity of missense variants based on a combination ofscores from 13 individual tools: MutPred, FATHMM v2.3, VEST 3.0, PolyPhen-2, SIFT, PROVEAN, MutationAssessor, MutationTaster, LRT, GERP++, SiPhy, phyloP, and phastCons.The REVEL score for an individual missense variant can range from 0 to 1, with higher scores reflecting greater likelihood that the variant is disease-causing. The variant was found inClinVar (Variant ID :15417) with a classification of Pathogenic/Likely Pathogenic and a review status of (2 star) criteria provided, multiple submitters, no conflicts. The variant is reported in many patients with beta thalassemia (Chen W et al.,2010). Based on the above evidence this variant has been classified as Pathogenic according to the ACMG guidelines.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Asian</Ethnicity>
              <GeographicOrigin>India</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <NamePlatform>NovaSeq 6000</NamePlatform>
              <TypePlatform>Next-generation exome sequencing</TypePlatform>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="CompoundHeterozygote" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB">
              <Name>hemoglobin subunit beta</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000518.5:exon 2</GeneLocation>
          </Location>
          <XRefList>
            <XRef DB="dbSNP" ID="rs80356821" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.126_129delCTTT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613985" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13006849</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3965928" SubmissionDate="2024-01-26" DateLastUpdated="2024-02-04" DateCreated="2021-11-29">
        <ClinVarSubmissionID localKey="b84e4ffda9fbed95051b69bf5310241f8191126bb5ab8afc820232f304682bc0|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002024957" DateUpdated="2024-02-04" DateCreated="2021-11-29" Type="SCV" Version="3" SubmitterName="Revvity Omics, Revvity" OrgID="167595" OrganizationCategory="laboratory" OrgAbbreviation="PKIG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-01-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.126_129del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10694847</SubmissionName>
          <SubmissionName>SUB12926214</SubmissionName>
          <SubmissionName>SUB14173319</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1850919" SubmissionDate="2024-02-07" DateLastUpdated="2024-02-28" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="1342345|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000956689" DateUpdated="2024-02-28" DateCreated="2019-08-14" Type="SCV" Version="6" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-31">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">23637309</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">6826539</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25089872</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28635337</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Phe42Leufs*19) in the HBB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in HBB are known to be pathogenic (PMID: 23637309). This variant is present in population databases (rs281864900, gnomAD 0.2%). This premature translational stop signal has been observed in individuals with HBB-related conditions (PMID: 6826539, 25089872, 28635337). ClinVar contains an entry for this variant (Variation ID: 15417). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.9:g.5247993_5247996del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12506961</SubmissionName>
          <SubmissionName>SUB14200269</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8819172" SubmissionDate="2024-03-08" DateLastUpdated="2024-03-16" DateCreated="2024-03-16">
        <ClinVarSubmissionID localKey="3569468|HBB-related condition" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004732710" DateUpdated="2024-03-16" DateCreated="2024-03-16" Type="SCV" Version="1" SubmitterName="PreventionGenetics, part of Exact Sciences" OrgID="239772" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-09">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The HBB c.126_129delCTTT variant is predicted to result in a frameshift and premature protein termination (p.Phe42Leufs*19). This variant was reported in individuals with beta-thalassemia (see for example Kazazian et al. 1984. PubMed ID: 6714226; Lau et al. 1997. PubMed ID: 9113933; Lin et al. 2021. PubMed ID: 34271589). This variant is reported in 0.23% of alleles in individuals of East Asian descent in gnomAD. Frameshift variants in HBB are expected to be pathogenic. This variant is interpreted as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.126_129delCTTT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">HBB-related condition</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14299258</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1363428" TraitType="Disease" MappingType="XRef" MappingValue="C0005283" MappingRef="MedGen">
        <MedGen CUI="C0005283" Name="beta Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1164935" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2282362" TraitType="Disease" MappingType="XRef" MappingValue="CN235283" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5459364" TraitType="Disease" MappingType="XRef" MappingValue="617971" MappingRef="OMIM">
        <MedGen CUI="C1840779" Name="METHEMOGLOBINEMIA, BETA TYPE" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7574095" TraitType="Finding" MappingType="XRef" MappingValue="HP:0000421" MappingRef="HP">
        <MedGen CUI="C0014591" Name="Epistaxis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2454031" TraitType="Disease" MappingType="Name" MappingValue="beta Thalassemia" MappingRef="Preferred">
        <MedGen CUI="C0005283" Name="beta Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="36943" TraitType="Disease" MappingType="Name" MappingValue="BETA-ZERO-THALASSEMIA" MappingRef="Preferred">
        <MedGen CUI="C0271980" Name="Beta zero thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2844131" TraitType="Disease" MappingType="XRef" MappingValue="141749" MappingRef="OMIM">
        <MedGen CUI="C0019025" Name="Hereditary persistence of fetal hemoglobin" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5459364" TraitType="Disease" MappingType="XRef" MappingValue="140700" MappingRef="OMIM">
        <MedGen CUI="C0700299" Name="Heinz body anemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1190083" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8819172" TraitType="Disease" MappingType="Name" MappingValue="HBB-related condition" MappingRef="Preferred">
        <MedGen CUI="CN239378" Name="HBB-related disorder" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5459364" TraitType="Disease" MappingType="XRef" MappingValue="613985" MappingRef="OMIM">
        <MedGen CUI="CN322236" Name="Beta-thalassemia HBB/LCRB" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7193227" TraitType="Disease" MappingType="XRef" MappingValue="613985" MappingRef="OMIM">
        <MedGen CUI="CN322236" Name="Beta-thalassemia HBB/LCRB" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5002466" TraitType="Disease" MappingType="XRef" MappingValue="613985" MappingRef="OMIM">
        <MedGen CUI="CN322236" Name="Beta-thalassemia HBB/LCRB" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7574095" TraitType="Finding" MappingType="XRef" MappingValue="HP:0005561" MappingRef="HP">
        <MedGen CUI="C4021634" Name="Abnormal bone marrow cell morphology" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1789583" TraitType="Disease" MappingType="XRef" MappingValue="613985" MappingRef="OMIM">
        <MedGen CUI="CN322236" Name="Beta-thalassemia HBB/LCRB" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7574095" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001915" MappingRef="HP">
        <MedGen CUI="C0002874" Name="Aplastic anemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5459364" TraitType="Disease" MappingType="XRef" MappingValue="603902" MappingRef="OMIM">
        <MedGen CUI="C1858990" Name="Dominant beta-thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2862763" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2354485" TraitType="Disease" MappingType="XRef" MappingValue="613985" MappingRef="OMIM">
        <MedGen CUI="CN322236" Name="Beta-thalassemia HBB/LCRB" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5459364" TraitType="Disease" MappingType="XRef" MappingValue="611162" MappingRef="OMIM">
        <MedGen CUI="C1970028" Name="Malaria, susceptibility to" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5459364" TraitType="Disease" MappingType="XRef" MappingValue="141749" MappingRef="OMIM">
        <MedGen CUI="C0019025" Name="Hereditary persistence of fetal hemoglobin" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1850919" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="40704" TraitType="Disease" MappingType="XRef" MappingValue="C0005283" MappingRef="MedGen">
        <MedGen CUI="C0005283" Name="beta Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1457141" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5459364" TraitType="Disease" MappingType="XRef" MappingValue="603903" MappingRef="OMIM">
        <MedGen CUI="C0002895" Name="Hb SS disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2292709" TraitType="Disease" MappingType="XRef" MappingValue="603903" MappingRef="OMIM">
        <MedGen CUI="C0002895" Name="Hb SS disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7574095" TraitType="Disease" MappingType="XRef" MappingValue="613985" MappingRef="OMIM">
        <MedGen CUI="CN322236" Name="Beta-thalassemia HBB/LCRB" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5459364" TraitType="Disease" MappingType="XRef" MappingValue="617980" MappingRef="OMIM">
        <MedGen CUI="C4693822" Name="Erythrocytosis, familial, 6" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5164797" TraitType="Disease" MappingType="XRef" MappingValue="C0950123" MappingRef="MedGen">
        <MedGen CUI="C0950123" Name="Inborn genetic diseases" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4083830" TraitType="Disease" MappingType="Name" MappingValue="Beta thalassemia" MappingRef="Preferred">
        <MedGen CUI="C0005283" Name="beta Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3965928" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5459364" TraitType="Disease" MappingType="XRef" MappingValue="604131" MappingRef="OMIM">
        <MedGen CUI="C0002312" Name="alpha Thalassemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

